Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
SIRPγ-expressing cancer stem-like cells promote immune escape of lung cancer via Hippo signaling
Chuan Xu, … , Xiu-Wu Bian, Hui-Kuan Lin
Chuan Xu, … , Xiu-Wu Bian, Hui-Kuan Lin
Published March 1, 2022
Citation Information: J Clin Invest. 2022;132(5):e141797. https://doi.org/10.1172/JCI141797.
View: Text | PDF
Research Article Immunology

SIRPγ-expressing cancer stem-like cells promote immune escape of lung cancer via Hippo signaling

  • Text
  • PDF
Abstract

Cancer stem-like cells (CSLCs) acquire enhanced immune checkpoint responses to evade immune cell killing and promote tumor progression. Here we showed that signal regulatory protein γ (SIRPγ) determined CSLC properties and immune evasiveness in a small population of lung adenocarcinoma (LUAD) cancer cells. A SIRPγhi population displayed CSLC properties and transmitted the immune escape signal through sustaining CD47 expression in both SIRPγhi and SIRPγlo/– tumor cells. SIRPγ bridged MST1 and PP2A to facilitate MST1 dephosphorylation, resulting in Hippo/YAP activation and leading to cytokine release by CSLCs, which stimulated CD47 expression in LUAD cells and consequently inhibited tumor cell phagocytosis. SIRPγ promoted tumor growth and metastasis in vivo through YAP signaling. Notably, SIRPγ targeting with genetic SIRPγ knockdown or a SIRPγ-neutralizing antibody inhibited CSLC phenotypes and elicited phagocytosis that suppressed tumor growth in vivo. SIRPG was upregulated in human LUAD and its overexpression predicted poor survival outcome. Thus, SIRPγhi cells serve as CSLCs and tumor immune checkpoint–initiating cells, propagating the immune escape signal to the entire cancer cell population. Our study identifies Hippo/YAP signaling as the first mechanism by which SIRPγ is engaged and reveals that targeting SIRPγ represents an immune- and CSLC-targeting strategy for lung cancer therapy.

Authors

Chuan Xu, Guoxiang Jin, Hong Wu, Wei Cui, Yu-Hui Wang, Rajesh Kumar Manne, Guihua Wang, Weina Zhang, Xian Zhang, Fei Han, Zhen Cai, Bo-Syong Pan, Che-Chia Hsu, Yiqiang Liu, Anmei Zhang, Jie Long, Hongbo Zou, Shuang Wang, Xiaodan Ma, Jinling Duan, Bin Wang, Weihui Liu, Haitao Lan, Qing Xiong, Gang Xue, Zhongzhu Chen, Zhigang Xu, Mark E. Furth, Sarah Haigh Molina, Yong Lu, Dan Xie, Xiu-Wu Bian, Hui-Kuan Lin

×

Figure 1

SIRPγ serves as a CSLC marker and promotes tumor growth.

Options: View larger image (or click on image) Download as PowerPoint
SIRPγ serves as a CSLC marker and promotes tumor growth.
(A) The normali...
(A) The normalized gene expression values of SIRPG, SIRPA, SIRPB1, and SIRPD in LUAD and adjacent normal tissues. (B and C) qRT-PCR analysis of the indicated genes in A549 cells grown in monolayer or spheres (B) or ALDH+ and ALDH– A549 cells (C). (D and E) Immunoblotting analysis of indicated proteins in A549 monolayers and spheres (D) or ALDH+ and ALDH– (E) A549 cells. (F) Flow cytometric analysis of the number of SIRPγhi A549 cells. (G) Stem cell sphere assay of SIRPγlo/– and SIRPγhi A549 cells (1 × 103 cells/well). (H) Immunoblotting analysis of indicated proteins in SIRPγlo/– and SIRPγhi A549 cells. (I) Tumor xenograft growth of SIRPγhi vs. SIRPγlo/– A549 cells (1 × 106 inoculated cells/mouse, mean ± SD, n = 5 mice). (J) Stem cell sphere assay of vector- and SIRPγ-overexpressing A549 cells (1 × 103 cells/well). (K) Stem cell sphere assay of control and SIRPγ-knockdown A549 cells (1 × 103 cells/well). All experiments were carried out at least in triplicate and the data are presented as the mean ± SD or mean ± SD. *P < 0.05; **P < 0.01 by paired or unpaired, 2-tailed Student’s t test. See complete unedited blots in the supplemental material.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts